WOBURN, Mass.--(BUSINESS WIRE)--Cambria Biosciences today unveiled a novel approach to discovering epilepsy drugs by utilizing an intact animal nervous system engineered for high-throughput screening. The process was described in a presentation made by Dr. Leo Liu, President and Chief Executive Officer at Cambria, at the 2nd Annual Neurotechnology Industry Organization Conference. The Company is currently using this discovery platform to build a pipeline of new epilepsy drug leads.
